Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in neuroscience and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is advancing research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. With approximately 9000 people worldwide, Biogen is truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to its research operations. Its international headquarters are based in Zug, Switzerland and it has world-class manufacturing facilities in Research Triangle Park, North Carolina. Biogen offers therapies to patients in 102 countries, with direct affiliate offices in 39 countries.